iShares U.S. Pharmaceuticals ETF
Eli Lilly’s Breakthrough Obesity Drug Retatrutide Triumphs in First Late-Stage Diabetes Trial: What It Means for You
Eli Lilly is making waves with its new obesity drug, retatrutide. Recently, it passed a critical late-stage trial focusing on ... Read more
Eli Lilly Unveils Innovative Zepbound: One Pen, One Month’s Supply – Revolutionizing Obesity Treatment!
Eli Lilly recently launched an exciting new version of its popular obesity drug, Zepbound. This new version comes in a ... Read more
Novo Nordisk Shares Drop 15% as Weight Loss Drug Fails to Compete with Eli Lilly’s Breakthrough in Latest Trial
Novo Nordisk’s stock dropped by 15% on Monday after news that its weight-loss drug, CagriSema, did not meet its main ... Read more
